Prognostic impact of baseline blood biomarkers in SCLC first-line treatment
Therapeutic Advances in Medical Oncology
Published online on May 25, 2026
Abstract
Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
Background:Small cell lung cancer (SCLC) is an aggressive malignancy with poor prognosis despite available treatment options. Although immunotherapy now constitutes the standard of care for extensive-stage SCLC (ES-SCLC), reliable biomarkers for patient ...
Background:Small cell lung cancer (SCLC) is an aggressive malignancy with poor prognosis despite available treatment options. Although immunotherapy now constitutes the standard of care for extensive-stage SCLC (ES-SCLC), reliable biomarkers for patient ...